Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00650637 · ClinicalTrials.gov registry record · Phase 3
A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
NCT00650637 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 17 participants.
The verdict
NCT00650637, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the efficacy and safety of calcium carbonate for the prevention of nelfinavir-associated diarrhea and to evaluate the efficacy and safety of calcium carbonate in combination with loperamide for the treatment of nelfinavir-associated diarrhea.
Interventions
- DRUG lamivudine
- DRUG Calcium Carbonate
- DRUG loperamide
- DRUG nelfinavir
- OTHER Calcium carbonate not administered
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2003-01 |
| Est. Completion | 2003-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00650637
The ClinicalTrials.gov registry entry for NCT00650637 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which lamivudine is the first listed.
NCT00650637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00650637 about?
NCT00650637 is a clinical study titled "A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea". The purpose of this study was to determine the efficacy and safety of calcium carbonate for the prevention of nelfinavir-associated diarrhea and to evaluate the efficacy and safety of calcium carbonate in combination with loperamide for the treatment of nelfinavir-associated diarrhea.
What is the current status of trial NCT00650637?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2003-01. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00650637?
The interventions under investigation include: lamivudine (DRUG), Calcium Carbonate (DRUG), loperamide (DRUG), nelfinavir (DRUG), Calcium carbonate not administered (OTHER).
Who is sponsoring clinical trial NCT00650637?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.